BYSI
BeyondSpring Inc.
stockNASDAQ
beyondspring pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. we are currently advancing the development of our lead asset plinabulin, a novel cancer therapeutic, in a global phase 3 trial in non-small-cell lung cancer (nsclc) and initiating a pivotal global phase 3 trial in prevention of docetaxel-induced neutropenia. as a tubulin depolymerizing agent, plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment: 1. immune enhancing effects via dendritic cell maturation 2. tumor cell apoptosis via activation of ras-jnk pathway 3. vascular disruptive effects given plinabulin's potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications: • immuno-oncology, with immune checkpoint inhibitors in nsclc • cns malignancies including glioblastoma (gbm) • kras positive mutant cancers
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.46 | 2026-10-26 | +76.09% | -7.971 |
| 1M | 0.79 | 2026-10-02 | +2.88% | -2.165 |
| 3M | 1.17 | 2026-08-03 | -30.77% | -1.817 |
| 6M | 1.49 | 2026-05-01 | -45.64% | 0.294 |
| 1Y | 2.07 | 2025-11-03 | -60.87% | 0.628 |
| 2Y | 2.23 | 2024-11-01 | -63.68% | — |
| 5Y | 14.72 | 2021-11-02 | -94.50% | 0.803 |
BeyondSpring Inc. (NASDAQ:BYSI) stock price today is $0.81, and today's volume is 1,182,975. BYSI is up 25.815% today. The 30 day average volume is 411,406. BYSI market cap is $33.31M with 41.12M shares outstanding.